Delveinsight

DECEMBER 10, 2020

Warding off Type 1 diabetes by aiming a T-cell protein. Scientists at the University of Utah School of Medicine have found a way to control that autoimmune response by aiming a protein that is vital for T-cell activation. The protein is known as OCA-B. UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3.

Gene Therapy 52

Gene Therapy Gene Vaccination Vaccine 52

The Pharma Data

JUNE 26, 2021

All current COVID-19 vaccines and antibody-based therapeutics were designed to disrupt this route into cells, which requires a receptor called ACE2. The ability to use an alternative entry pathway opens up the possibility of evading COVID-19 antibodies or vaccines, but the researchers did not find evidence of such evasion.

Antibody 52

Antibody Vaccination Vaccine Research 52

The Pharma Data

MARCH 22, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. The Phase III D8110C00001 trial is part of this funding agreement. JPEO-CBRND. Source link:[link].

Trials 52

Trials Vaccination Vaccine Radiology 52

The Pharma Data

MAY 16, 2021

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. Overall, the vaccine candidate elicited strong neutralizing antibody levels that were comparable to those generated by natural infection, with higher levels observed in younger adults (18 to 59 years old).

Immune Response 52

Immune Response Vaccination Vaccine Trials 52

The Pharma Data

JUNE 25, 2021

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. W911QY-21-9-0001.

Trials 52

Trials Antibody In-Vitro Medicine 52

XTalks

AUGUST 30, 2022

Such therapies may involve small interfering RNA (siRNA) or oligonucleotides in viral transfection platforms, large molecules and antibodies. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets? Vornov, nusinersen is driving much of what is being currently seen in drug development.

Trials 83

Trials Drug Delivery Drugs Gene 83

The Pharma Data

DECEMBER 23, 2020

Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” mg dose group and 84% demonstrating neutralizing antibodies in the 2.0 mg and 2.0 The 1.0

DNA 40

DNA Vaccine Vaccination Immune Response 40

XTalks

JUNE 12, 2023

Siemens Healthineers further demonstrated its commitment to innovation at the European Congress of Radiology in Vienna, showcasing its revamped Acuson ultrasound portfolio. In addition, the company received FDA approval for the Pathway anti-HER2 (4B5) Antibody assay , intended to detect HER2 protein in patients with breast cancer.

FDA Approval 98

FDA Approval Production Sales In-Vitro 98

XTalks

NOVEMBER 7, 2022

Another method to isolate CTCs is by antibody targeting of white blood cells for removal, followed by collection of untagged CTCs. Exosomes are extracellular vesicles that contain molecular cargoes (such as various proteins, RNAs and DNAs) specific to the origin cell. Exosome-Based Liquid Biopsy in Oncology.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

The Pharma Data

OCTOBER 6, 2021

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Juncture Use Authorization (EUA) for AZD7442, its long- production antibody (LAAB) combination, for prophylaxis of proper COVID-19. Notwithstanding, AZD7442 would be the first LAAB to take an EUA for COVID-19 precluding, If granted. W911QY-21-9-0001.

Antibody 52

Antibody In-Vitro Trials Development 52

XTalks

SEPTEMBER 14, 2020

Moderna, for one, recently reported positive results in older adults between 56 and 71, as well as those 71 years of age and older, who reportedly mounted levels of neutralizing antibodies against the SARS-CoV-2 virus after two doses of its vaccine that were comparable to those seen in younger adults. Johnson & Johnson’s COVID-19 Vaccine.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92